
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Balchem Corporation (BCPC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BCPC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $200.33
1 Year Target Price $200.33
0 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.75% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.26B USD | Price to earnings Ratio 37.15 | 1Y Target Price 200.33 |
Price to earnings Ratio 37.15 | 1Y Target Price 200.33 | ||
Volume (30-day avg) 2 | Beta 0.89 | 52 Weeks Range 145.70 - 184.99 | Updated Date 08/29/2025 |
52 Weeks Range 145.70 - 184.99 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 0.53% | Basic EPS (TTM) 4.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.48% | Operating Margin (TTM) 20.3% |
Management Effectiveness
Return on Assets (TTM) 7.66% | Return on Equity (TTM) 11.99% |
Valuation
Trailing PE 37.15 | Forward PE 36.63 | Enterprise Value 5399666714 | Price to Sales(TTM) 5.33 |
Enterprise Value 5399666714 | Price to Sales(TTM) 5.33 | ||
Enterprise Value to Revenue 5.48 | Enterprise Value to EBITDA 22.3 | Shares Outstanding 32455200 | Shares Floating 32283505 |
Shares Outstanding 32455200 | Shares Floating 32283505 | ||
Percent Insiders 0.37 | Percent Institutions 90.93 |
Upturn AI SWOT
Balchem Corporation

Company Overview
History and Background
Balchem Corporation was founded in 1967. Initially focused on encapsulation technology, Balchem has grown through organic expansion and strategic acquisitions, evolving into a global leader in specialty ingredients.
Core Business Areas
- Human Nutrition & Health: Supplies ingredients for food and beverage, and dietary supplement markets, including encapsulated nutrients and minerals.
- Animal Nutrition & Health: Provides solutions to improve animal health and productivity, including chelated minerals, rumen-protected nutrients, and feed supplements.
- Specialty Products: Offers products for industrial applications, including choline chloride and other performance chemicals used in various industries.
Leadership and Structure
Ted Harris is the Chairman, President, and CEO. The company operates with a functional organizational structure with distinct business segments, each led by a vice president, reporting to the CEO.
Top Products and Market Share
Key Offerings
- VitaCholine: Choline ingredient used in dietary supplements and infant formula. Balchem holds a significant market share in the global choline market. Competitors include Jubilant Ingrevia, BASF, and Alkyl Amines Chemicals.
- Reashure: Rumen-protected choline for dairy cows, designed to improve milk production and overall health. Balchem is a leading provider in this market. Competitors include DuPont, ADM, and Cargill.
- AminoShure-XM: Precision release rumen protected lysine that is used to ensure the animal receives the nutrients needed to thrive. Competitors include DuPont, ADM, and Cargill.
Market Dynamics
Industry Overview
The specialty ingredients market is driven by increasing demand for healthier food and beverage options, growing animal protein consumption, and advancements in encapsulation technology.
Positioning
Balchem is positioned as a leader in encapsulation and chelation technologies, enabling delivery of nutrients and functional ingredients. Its focus on science-backed solutions gives it a competitive advantage.
Total Addressable Market (TAM)
The global specialty ingredients market is estimated at hundreds of billions USD. Balchem focuses on specific niches within these broader markets, targeting growth opportunities with high-value products and solutions. Balchem holds a percentage of this TAM.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Leading technology in encapsulation and chelation
- Diversified product portfolio
- Global presence
- Strong financial performance
Weaknesses
- Reliance on specific suppliers for raw materials
- Exposure to commodity price fluctuations
- Limited brand recognition outside core markets
- Dependence on key patents
Opportunities
- Expansion into new geographic markets
- Development of innovative products
- Acquisitions of complementary businesses
- Growing demand for specialty ingredients
- Increase in pet ownership
Threats
- Increased competition
- Changes in regulations
- Economic downturns
- Raw material price volatility
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- IFF (IFF)
- DSM (DSM.AS)
- ADM (ADM)
Competitive Landscape
Balchemu2019s competitive advantage lies in its strong technology platform, diversified product portfolio, and focus on high-value markets. Competitors have broader portfolios but may lack Balchemu2019s specialization.
Major Acquisitions
Performance Chemicals
- Year: 2016
- Acquisition Price (USD millions): 93.9
- Strategic Rationale: Expanded Balchem's Specialty Products segment by adding choline chloride and other performance chemicals.
Bergstrom Nutrition
- Year: 2020
- Acquisition Price (USD millions): 133.5
- Strategic Rationale: Expanded Balchem's Human Nutrition & Health segment by adding OptiMSM.
Growth Trajectory and Initiatives
Historical Growth: Balchem has achieved consistent revenue and earnings growth through organic expansion and strategic acquisitions.
Future Projections: Analysts project continued revenue and earnings growth, driven by demand for specialty ingredients and expansion into new markets. The projected earnings growth rate is at low double digits %.
Recent Initiatives: Recent initiatives include acquisitions, expansion of manufacturing facilities, and investments in research and development.
Summary
Balchem Corporation shows a strong business model with a proven track record of growth through strategic acquisitions and innovative product development. They hold a robust position in their niche markets, though reliance on raw material suppliers and potential commodity price volatility are risks. Future growth is expected to continue with expansion into new markets and continued investment in R&D. Overall, Balchem is fundamentally solid but needs to monitor competition and manage supply chain risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Balchem Corporation's Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Balchem Corporation
Exchange NASDAQ | Headquaters Montvale, NJ, United States | ||
IPO Launch date 1986-06-03 | CEO, President & Chairman Mr. Theodore Lee Harris | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 1364 | Website https://www.balchem.com |
Full time employees 1364 | Website https://www.balchem.com |
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.